Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
What dose would you treat a patient to for a positive deep skeletal muscle margin after mastectomy who is not a candidate for re-resection?
Answer from: Radiation Oncologist at Community Practice
I would offer PMRT and boost the area of positive margin to 60-66 Gy based on pre op imaging and extent of positivity seen on pathology
Sign In
or
Register
to read more
3220
Related Questions
In a patient with T2N0 breast cancer with skin involvement s/p lumpectomy and negative margins, if you are offering whole breast radiation, would you bolus your tangent fields?
Is it reasonable to extrapolate the findings of RT Charm and Alliance to intact breast patients and offer hypofractionated RNI to all patients who are eligible for RNI?
Is it appropriate to use bolus with hypofractionated PMRT?
Does pre-chemotherapy extent of nodal involvement impact your decision to offer adjuvant radiation in cN1, ypN0 triple-negative breast cancer?
How do the results of INSEMA and SOUND impact the decision of omitting SLND in young women with breast cancer and offering adjuvant RT to patients who would otherwise be candidates for omission?
Does a high genomic risk score impact your radiation fields for patients with breast cancer?
Is FAST-Forward/ultra-hypofractionation suitable for an early-stage breast patient after a lumpectomy with oncoplastic reduction?
How do you assess and counsel women with chronic post-lumpectomy or mastectomy pain?
Would you consider whole breast re-irradiation in a patient with a second/recurrent breast cancer and prior history of breast radiation therapy many years ago, if the tumor characteristics are not amenable to partial breast re-irradiation?
Would you offer ultrahypofractionated 5-fraction whole breast only for a women with ER-/HER2+/cN+ disease with pCR following neoadjuvant systemic therapy?